semaglutide weight loss greeley co Medical GLP-1 in Colorado (CO) Semaglutide Weight Loss Injections &

Peacock BN, Gherezghiher TB, Hilario JD, Kellermann GH

Phase 2 Trial Design Participants: 338 adults with obesity (BMI 30) or overweight with comorbidities (BMI 27), without diabetes Duration: 48 weeks Dosing groups: Placebo, 1mg, 4mg, 8mg, or 12mg weekly (with gradual dose escalation over 20-24 weeks) Primary endpoint: Percentage change in body weight from baseline Beyond Weight Loss: Metabolic Improvements Beyond weight loss, the 12mg dose also improved several cardiometabolic markers: Blood pressure: Systolic BP decreased by 7.4 mmHg (clinically significant reduction) Lipids: Triglycerides fell 30%, HDL cholesterol increased 8% Glucose control: HbA1c decreased 0.4% even in participants without diabetes Liver health: Markers of fatty liver disease (ALT, AST) improved significantly Inflammation: C-reactive protein (CRP) decreased, indicating reduced systemic inflammation What this means: Retatrutide appears to improve the metabolic dysfunction behind obesity-related diseases, not just the weight itself

Though there has been some preliminary data that GLP-1RAs might protect against cognitive decline and dementia, the research is still in clinical trials

This makes us an ideal partner for international procurement

Maps failed to load Sorry, unable to load the Maps API

The gastrointestinal side effects can vary